Targeted intracellular delivery of resveratrol to glioblastoma cells using apolipoprotein E-containing Reconstituted HDL as a nanovehicle

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Kim, Sea H ^a   Adhikari, Birendra Babu ^a   Cruz, Siobanth ^a   Schramm, Michael P ^a   Vinson, Joe A ^b   Narayanaswami, Vasanthy ^a  

^a CALIFORNIA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF SCRANTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E3; DRUG VEHICLE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PHOSPHOLIPID; RESVERATROL; 7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL; ANTINEOPLASTIC AGENT; FLUORESCENT DYE; NITROBENZENE DERIVATIVE; PYRROLE DERIVATIVE; STILBENE DERIVATIVE;

ARTICLE; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG EFFECT; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSPORT; ENDOCYTOSIS; ENDOSOME; FLUORESCENCE; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; INTERNALIZATION; INTRACELLULAR TRANSPORT; LYSOSOME; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE; PARTICLE SIZE; PHOSPHOLIPID BILAYER; CHEMICAL PHENOMENA; CHEMISTRY; DRUG EFFECTS; GLIA; METABOLISM; PATHOLOGY; PROCEDURES; PROTEIN TERTIARY STRUCTURE; STAINING; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOLIPOPROTEIN E3; AZOLES; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; ENDOSOMES; FLUORESCENT DYES; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIPOPROTEINS, HDL; NEUROGLIA; NITROBENZENES; PARTICLE SIZE; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, LDL; STAINING AND LABELING; STILBENES;

EID: 84942673559     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0135130     Document Type: Article

References (57)

1. Vang O, Ahmad N, Baile CA, Baur JA, Brown K, Csiszar A, et al. (2011) What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoSOne 6:e19881. doi: 10.1371/journal.pone.0019881 PMID: 21698226
2. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, et al. (1997) Cancerchemopreventive activity of resveratrol, a natural product derived from grapes. Science 275:218-220. PMID: 8985016
3. Pal S, Ho N, Santos C, Dubois P, Mamo J, Croft K, et al. (2003) Red wine polyphenols increase LDL receptor expression and activity and suppress the secretion of ApoB100 from human HepG2 cells. J Nutr 133:700-706. PMID: 12612140
4. Khadem-Ansari MH, Rasmi Y, Ramezani F (2010) Effects of red grape juice consumption on high density lipoprotein-cholesterol, apolipoprotein AI, apolipoprotein B and homocysteine in healthy human volunteers. Open Biochem J 4:96-99. doi: 10.2174/1874091X01004010096 PMID: 21633724
5. Salas M, Obando P, Ojeda L, Ojeda P, Perez A, Vargas-Uribe M, et al. (2013) Resolution of the direct interaction with and inhibition of the human GLUT1 hexose transporter by resveratrol from its effect on glucose accumulation. Am J Physiol Cell Physiol 305:C90-99. doi: 10.1152/ajpcell.00387.2012 PMID: 23615963
6. Frankel EN, Waterhouse AL, Kinsella JE (1993) Inhibition of human LDL oxidation by resveratrol. Lancet 341:1103-1104.
7. De La Lastra CA, Villegas I (2007) Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications. Biochem Soc Trans 35:1156-1160. PMID: 17956300
8. Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H, et al. (2012) Resveratrol ameliorates agingrelated metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148:421-433. doi: 10. 1016/j.cell.2012.01.017 PMID: 22304913
9. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, et al. (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127:1109-1122. PMID: 17112576
10. Planas JM, Alfaras I, Colom H, Juan ME (2012) The bioavailability and distribution of trans-resveratrol are constrained by ABC transporters. Arch Biochem Biophys 527:67-73. doi: 10.1016/j.abb.2012.06. 004 PMID: 22750234
11. Leonarduzzi G, Testa G, Sottero B, Gamba P, Poli G (2010) Design and development of nanovehiclebased delivery systems for preventive or therapeutic supplementation with flavonoids. Curr Med Chem 17:74-95. PMID: 19941477
12. Walle T, Hsieh F, De Legge MH, Oatis JE Jr, Walle UK (2004) High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32:1377-1382. PMID: 15333514
13. Kuhnle G, Spencer JP, Chowrimootoo G, Schroeter H, Debnam ES, Srai SK, et al. (2000) Resveratrol is absorbed in the small intestine as resveratrol glucuronide. Biochem Biophys Res Commun 272:212-217. PMID: 10872829
14. Miksits M, Maier-Salamon A, Aust S, Thalhammer T, Reznicek G, Kunert O, et al. (2005) Sulfation of resveratrol in human liver: evidence of a major role for the sulfotransferases SULT1A1 and SULT1E1. Xenobiotica 35:1101-1119. PMID: 16418064
15. Burkon A, Somoza V (2008) Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O-conjugated diglucuronides-two novel resveratrol metabolites in human plasma. Mol Nutr Food Res 52:549-557. doi: 10.1002/mnfr.200700290 PMID: 18435437
16. Brown KA, Simpson ER (2010) Obesity and breast cancer: progress to understanding the relationship. Cancer Res 70:4-7. doi: 10.1158/0008-5472. CAN-09-2257 PMID: 20028864
17. Tak JK, Lee JH, Park JW (2012) Resveratrol and piperine enhance radiosensitivity of tumor cells. BMB Rep 45:242-246. PMID: 22531135
18. Biasutto L, Zoratti M (2014) Prodrugs of quercetin and resveratrol: a strategy under development. Curr Drug Metab 15:77-95. PMID: 24329110
19. Liang L, Liu X, Wang Q, Cheng S, Zhang S, Zhang M (2013) Pharmacokinetics, tissue distribution and excretion study of resveratrol and its prodrug 3, 5, 4'-tri-O-acetylresveratrol in rats. Phytomedicine 20:558-563. doi: 10.1016/j.phymed.2012.12.012 PMID: 23351959
20. Sundara Rajan S, Turovskiy Y, Singh Y, Chikindas ML, Sinko PJ (2014) Poly (ethylene glycol) (PEG) - lactic acid nanocarrier-based degradable hydrogels for restoring the vaginal microenvironment. J Control Release 194:301-309. doi: 10.1016/j.jconrel.2014.08.031 PMID: 25223229
21. Amri A, Chaumeil JC, Sfar S, Charrueau C (2012) Administration of resveratrol: What formulation solutions to bioavailability limitations? J Control Release 158:182-193. doi: 10.1016/j.jconrel.2011.09.083 PMID: 21978644
22. Pangeni R, Sahni JK, Ali J, Sharma S, Baboota S (2014) Resveratrol: review on therapeutic potential and recent advances in drug delivery. Expert Opin Drug Deliv 11:1285-1298. doi: 10.1517/17425247. 2014.919253 PMID: 24830814
23. Hatters DM, Peters-Libeu CA, Weisgraber KH (2006) Apolipoprotein E structure: insights into function. Trends Biochem Sci 31:445-454. PMID: 16820298
24. Phillips MC (2014) Apolipoprotein E isoformsand lipoprotein metabolism. IUBMB Life 66:616-623. doi: 10.1002/iub.1314 PMID: 25328986
25. Weisgraber KH (1994) Apolipoprotein E: structure-function relationships. Adv Protein Chem 45:249-302. PMID: 8154371
26. Raussens V, Fisher CA, Goormaghtigh E, Ryan RO, Ruysschaert JM (1998) The low density lipoprotein receptor active conformation of apolipoprotein E. Helix organization in n-terminal domain-phospholipid disc particles. J Biol Chem 273:25825-25830. PMID: 9748256
27. Gupta V, Narayanaswami V, Budamagunta MS, Yamamato T, Voss JC, Ryan RO (2006) Lipid-induced extension of apolipoprotein E helix 4 correlates with low density lipoprotein receptor binding ability. J Biol Chem 281:39294-39299. PMID: 17079229
28. Narayanaswami V, Maiorano JN, Dhanasekaran P, Ryan RO, Phillips MC, Lund-Katz S, et al. (2004) Helix orientation of the functional domains in apolipoprotein e in discoidal high density lipoprotein particles. J Biol Chem 279:14273-14279. PMID: 14739281
29. Lakowicz JR (1999) Principles of fluorescence spectroscopy, 2nded., KluwerAcademic/Plenum, New York.
30. Eftink MR, Ghiron CA (1976) Exposure of tryptophanyl residues in proteins. Quantitative determination by fluorescence quenching studies. Biochemistry 15:672-680. PMID: 1252418
31. Fisher C, Abdul-Aziz D, Blacklow SC (2004) A two-module region of the low-density lipoprotein receptor sufficient for formation of complexes with apolipoprotein E ligands. Biochemistry 43:1037-1044. PMID: 14744149
32. Khumsupan P, Ramirez R, Khumsupan D, Narayanaswami V (2011) Apolipoprotein E LDL receptorbinding domain-containing high-density lipoprotein: a nanovehicle to transport curcumin, an antioxidant and anti-amyloid bioflavonoid. Biochim Biophys Acta 1808:352-359. doi: 10.1016/j.bbamem.2010.09. 007 PMID: 20851099
33. Lehrer SS (1971) Solute perturbation of protein fluorescence. The quenching of the tryptophyl fluorescence of model compounds and of lysozyme by iodide ion. Biochemistry 10:3254-3263. PMID: 5119250
34. Abrams FS, London E (1992) Calibration of the parallax fluorescence quenching method for determination of membrane penetration depth: refinement and comparison of quenching by spin-labeled and brominated lipids. Biochemistry 31:5312-5322. PMID: 1606155
35. Adhikari BB, Fujii A, Schramm MP (2014) Calixarene-Mediated Liquid-Membrane Transport of Choline Conjugates. European Journal of Organic Chemistry 2014:2972-2979. PMID: 26161034
36. Pal A, Hall BS, Field MC (2002) Evidence for a non-LDL-mediated entry route for the trypanocidal drug suramin in Trypanosoma brucei. Mol Biochem Parasitol 122:217-221. PMID: 12106876
37. Nath A, Atkins WM, Sligar SG (2007) Applications of phospholipid bilayer nanodiscs in the study of membranes and membrane proteins. Biochemistry 46:2059-2069. PMID: 17263563
38. Pervaiz S (2003) Resveratrol: from grapevines to mammalian biology. FASEB J 17:1975-1985. PMID: 14597667
39. Figueiras TS, Neves-Petersen MT, Petersen SB (2011) Activation energy of light induced isomerization of resveratrol. J Fluoresc 21:1897-1906. doi: 10.1007/s10895-011-0886-3 PMID: 21494846
40. Belguendouz L, Fremont L, Gozzelino MT (1998) Interaction oftransresveratrol with plasma lipoproteins. Biochem Pharmacol 55:811-816. PMID: 9586953
41. Jannin B, Menzel M, Berlot JP, Delmas D, Lancon A, Latruffe N (2004) Transport of resveratrol, a cancer chemopreventive agent, to cellular targets: plasmatic protein binding and cell uptake. Biochem Pharmacol 68:1113-1118. PMID: 15313407
42. Delmas D, Lin HY (2011) Role of membrane dynamics processes and exogenous molecules in cellular resveratrol uptake: consequences in bioavailability and activities. Mol Nutr Food Res 55:1142-1153. doi: 10.1002/mnfr.201100065 PMID: 21648069
43. Nikanjam M, Blakely EA, Bjornstad KA, Shu X, Budinger TF, Forte TM (2007) Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme. Int J Pharm 328:86-94. PMID: 16959446
44. Maletinska L, Blakely EA, Bjornstad KA, Deen DF, Knoff LJ, Forte TM (2000) Human glioblastoma cell lines: levels of low-density lipoprotein receptor and low-density lipoprotein receptor-related protein. Cancer Res 60:2300-2303. PMID: 10786698
45. Herz J, Strickland DK (2001) LRP: a multifunctional scavenger and signaling receptor. J Clin Invest 108:779-784. PMID: 11560943
46. Yamamoto M, Ikeda K, Ohshima K, Tsugu H, Kimura H, Tomonaga M (1997) Increased expression of low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor in human malignant astrocytomas. Cancer Res 57:2799-2805. PMID: 9205092
47. Chung NS, Wasan KM (2004) Potential role of the low-density lipoprotein receptor family as mediators of cellular drug uptake. Adv Drug Deliv Rev 56:1315-1334. PMID: 15109771
48. Holtzman DM, Herz J, Bu G (2012) Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb PerspectMed 2:a006312. doi: 10.1101/cshperspect.a006312 PMID: 22393530
49. Caddeo C, Teskac K, Sinico C, Kristl J (2008) Effect of resveratrol incorporated in liposomes on proliferation and UV-B protection of cells. Int J Pharm 363:183-191. doi: 10.1016/j.ijpharm.2008.07.024 PMID: 18718515
50. Torchilin VP (2007) Targeted pharmaceutical nanocarriersforcancertherapy and imaging. AAPS J 9:E128-147. PMID: 17614355
51. Jain A, Gulbake A, Shilpi S, Hurkat P, Jain SK (2013) Peptide and protein delivery using new drug delivery systems. Crit Rev Ther Drug Carrier Syst 30:293-329. PMID: 23662604
52. Teskac K, Kristl J (2010) The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int J Pharm 390:61-69. doi: 10.1016/j.ijpharm.2009.10.011 PMID: 19833178
53. Seeman P, Seeman N (2011) Alzheimer's disease: beta-amyloid plaque formation in human brain. Synapse 65:1289-1297. doi: 10.1002/syn. 20957 PMID: 21633975
54. Li J, Kanekiyo T, Shinohara M, Zhang Y, La Du MJ, Xu H, et al. (2012) Differential regulation of amyloidbeta endocytic trafficking and lysosomal degradation by apolipoprotein E isoforms. J Biol Chem 287:44593-44601. doi: 10.1074/jbc. M112.420224 PMID: 23132858
55. Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA (2000) Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol 157:277-286. PMID: 10880397
56. Frozza RL, Bernardi A, Hoppe JB, Meneghetti AB, Matte A, Battastini AM, et al. (2013) Neuroprotective Effects of Resveratrol Against Abeta Administration in Rats are Improved by Lipid-Core Nanocapsules. Mol Neurobiol 47:1066-1080. doi: 10.1007/s12035-013-8401-2 PMID: 23315270
57. Feng X, Liang N, Zhu D, Gao Q, Peng L, Dong H, et al. (2013) Resveratrol inhibits beta-amyloidinduced neuronal apoptosis through regulation of SIRT1-ROCK1 signaling pathway. PLoS One 8:e59888. doi: 10.1371/journal.pone.0059888 PMID: 23555824